EGFR and Patent ductus arteriosus: In addition to significant benefit in treatment-naïve non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations, afatinib has shown notable efficacy in tumors, including PDA, harboring neuregulin (NRG1) fusions, as seen in the basket study TAPUR [52].